Wed, December 11, 2024
Tue, December 10, 2024
[ Tue, Dec 10th 2024 ]: The New Yorker
The Dawn of the Bionic Man
[ Tue, Dec 10th 2024 ]: Mercury News
California News
[ Tue, Dec 10th 2024 ]: ABC News
Entertainment News
Mon, December 9, 2024
[ Mon, Dec 09th 2024 ]: BBC
Beds, Herts & Bucks
[ Mon, Dec 09th 2024 ]: Uproxx
The Best TV Shows Of 2024
[ Mon, Dec 09th 2024 ]: Paste
The 25 Best PC Games of 2024
[ Mon, Dec 09th 2024 ]: CNET
Top News Stories
Sun, December 8, 2024
Sat, December 7, 2024
[ Sat, Dec 07th 2024 ]: Newsweek
Russia-Ukraine War
[ Sat, Dec 07th 2024 ]: imdb.com
Canada's 30 Funniest TV Shows
[ Sat, Dec 07th 2024 ]: Daily Mail
UK Celebrity News
[ Sat, Dec 07th 2024 ]: Food Safety News
Food Safety News
Fri, December 6, 2024
[ Fri, Dec 06th 2024 ]: Graphic
Latest Ghana News Headlines Today
[ Fri, Dec 06th 2024 ]: The Columbian
Clark County News
[ Fri, Dec 06th 2024 ]: who13
Cyclones react to 10 wins
[ Fri, Dec 06th 2024 ]: TravelPulse
Hotels and Resorts News
[ Fri, Dec 06th 2024 ]: Business Standard
Share Market Today
[ Fri, Dec 06th 2024 ]: Reuters
Aerospace & Defense
Thu, December 5, 2024
[ Thu, Dec 05th 2024 ]: Interest
All news stories
[ Thu, Dec 05th 2024 ]: Paste
The 30 Best TV Shows of 2024
[ Thu, Dec 05th 2024 ]: Phil Bruner
Featured News Stories
[ Thu, Dec 05th 2024 ]: Phil Bruner
Swattie Survival Guide
Wed, December 4, 2024
[ Wed, Dec 04th 2024 ]: Phil Bruner
California News
[ Wed, Dec 04th 2024 ]: Phil Bruner
President Joe Biden
Tue, December 3, 2024
[ Tue, Dec 03rd 2024 ]: Phil Bruner
The 40 Best Games of 2024
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Boku No Roblox Codes
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Yonhap News Agency
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Beds, Herts & Bucks
[ Tue, Dec 03rd 2024 ]: Phil Bruner
Transfer news and rumors
Mon, December 2, 2024
[ Mon, Dec 02nd 2024 ]: Phil Bruner
Watch Samaa News Live
[ Mon, Dec 02nd 2024 ]: Phil Bruner
UK Celebrity News
[ Mon, Dec 02nd 2024 ]: Phil Bruner
The 100 Best Albums of 2024
[ Mon, Dec 02nd 2024 ]: Phil Bruner
From the Newspaper
[ Mon, Dec 02nd 2024 ]: Phil Bruner
South Australia
[ Mon, Dec 02nd 2024 ]: Phil Bruner
Whanganui Chronicle
Sun, December 1, 2024
[ Sun, Dec 01st 2024 ]: Phil Bruner
Wildlife Oddities of the Week
Sat, November 30, 2024
Fri, November 29, 2024
[ Fri, Nov 29th 2024 ]: Phil Bruner
Hotels and Resorts News
[ Fri, Nov 29th 2024 ]: Phil Bruner
The Best Jokes of 2024
Thu, November 28, 2024
[ Thu, Nov 28th 2024 ]: Phil Bruner
Climate and Environment
[ Thu, Nov 28th 2024 ]: Phil Bruner
December 2024 Issue
Wed, November 27, 2024
[ Wed, Nov 27th 2024 ]: Phil Bruner
Decoding Gen Z's content diet
Tue, November 26, 2024
[ Tue, Nov 26th 2024 ]: Phil Bruner
Illustrated Humor in the News
[ Tue, Nov 26th 2024 ]: Phil Bruner
World News
[ Tue, Nov 26th 2024 ]: Phil Bruner
Alexandra Petri
Mon, November 25, 2024
[ Mon, Nov 25th 2024 ]: Phil Bruner
All Kent news
Sun, November 24, 2024
Mon, December 15, 2008
[ Mon, Dec 15th 2008 ]: Market Wire
fasdfasddva s gfg h

Isis Pharmaceuticals to Present at the 2013 Leerink Swann Global Healthcare Conference

  Copy link into your clipboard //health-fitness.news-articles.net/content/2013/ .. -leerink-swann-global-healthcare-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

Isis Pharmaceuticals to Present at the 2013 Leerink Swann Global Healthcare Conference -- CARLSBAD, Calif., Feb. 7, 2013 /PRNewswire/ --

CARLSBAD, Calif., Feb. 7, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: [ ISIS ]), the leader in antisense therapeutics, today announced that management will present a company overview at the 2013 Leerink Swann Healthcare Conference on Thursday, February 14, 2013 at 12:00 p.m. ET in New York, NY.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, [ www.isispharm.com ].  A replay will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets, including Europe.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at [ www.isispharm.com ].

FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals, Inc.



RELATED LINKS
[ http://www.isispharm.com ]